Synergism of Telmisartan and Amlodipine on Blood Pressure Reduction and Cardiorenal Protection in Hypertensive Rats
Authors:
- Wei WangWWWei Wang
- Shu-Wei SongSSShu-Wei Song
- Xiao-Fei GuXGXiao-Fei Gu
- Xiu-Juan MaXMXiu-Juan Ma
- Feng-Yun SuFSFeng-Yun Su
- Hao ZhangHZHao Zhang
- Ai-Jun LiuALAi-Jun Liu
- Ding-Feng SuDSDing-Feng Su
- 1 March 2011
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 57 (3) , 308-316
Abstract
This study was designed to investigate the effects of telmisartan and amlodipine on reduction of blood pressure (BP), myocardial hypertrophy, and renal injury in hypertensive rats. In acute experiments, the BP was measured in conscious freely moving rats. Spontaneously hypertensive rats were treated with intragastric administration of amlodipine (1, 2, 4 mg/kg), telmisartan (4, 8, 12, 16, 20 mg/kg), and their different combinations (4 + 4, 2 + 4, 4 + 8, 4 + 12, 1 + 4, 2 + 8, 4 + 16, 2 + 12, 1 + 8, 2 + 16, 2 + 20, 1 + 12, 1 + 16, 1 + 20 mg/kg). The probability sum test (q test) was used to evaluate the synergistic action on BP reduction. In two-kidney, one-clip rats, the effects of amlodipine (1 mg/kg), telmisartan (6 mg/kg) and their combination on BP reduction were observed. In the chronic study, spontaneously hypertensive rats were treated with amlodipine (1 mg/kg), telmisartan (6 mg/kg), and their combination for 4 months. Histopathologic examinations were performed after the determination of BP and BP variability. There is a synergistic interaction between amlodipine and telmisartan on BP reduction. The optimal dose ratio was found at 1:6. The synergistic effect of this dose ratio (1:6) was also seen in two-kidney, one-clip rats. Long-term treatment with this combination results in a beneficial effect on the reduction of BP and BP variability. The end-organ damage, including myocardial hypertrophy, glomerular atrophy, and fibrosis, was significantly attenuated by this combination. The optimal dose ratio of amlodipine and telmisartan on BP was 1:6. This combination is beneficial for the BP and BP variability reduction and end-organ damage prevention.Keywords
This publication has 28 references indexed in Scilit:
- Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin–angiotensin–aldosterone system blockersJournal Of Hypertension, 2010
- Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive ratsClinical and Experimental Pharmacology and Physiology, 2009
- EFFECT OF CALCIUM CHANNEL BLOCKADE ON ADRENERGICALLY INDUCED RENAL VASOCONSTRICTION IN RAT MODELS OF RENAL IMPAIRMENTClinical and Experimental Pharmacology and Physiology, 2009
- Effects of allisartan, a new AT1 receptor blocker, on blood pressure and end-organ damage in hypertensive animalsActa Pharmacologica Sinica, 2009
- Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trialJournal Of Hypertension, 2008
- PRESSOR AND NON‐PRESSOR EFFECTS OF SODIUM LOADING ON STROKE IN STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATSClinical and Experimental Pharmacology and Physiology, 2007
- Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive ratsJournal Of Hypertension, 2005
- Hypertensive Therapy: Part IICirculation, 2004
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats.Hypertension, 1992